← The Wire
FBRXNasdaq
Forte Biosciences, Inc.
Pharmaceutical Preparations · DE · CIK 1419041
Forte Biosciences develops a proprietary antibody therapeutic candidate for autoimmune and autoimmune-related indications
red 8-K · 90d
$360M
Market cap
$21.32
Last close
+1.4%
1D
+16.6%
5D
475K
Volume
Price · last 39 sessions-25.2%
May 4L $15.67 · H $28.51Jun 29
202
Total filings
Jun 2, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteJun 2, 20268-KResults of OperationsMay 14, 202610-Q10-QMay 11, 2026DEF 14ADEF 14AApr 29, 2026424B5424B5Apr 9, 20268-KMaterial Agreement · Reg FD DisclosureApr 9, 2026424B5424B5Apr 8, 20268-KResults of OperationsApr 1, 202610-K10-KMar 31, 202610-Q10-QNov 14, 20258-KResults of OperationsNov 14, 202510-Q10-QAug 14, 20258-KResults of Operations · Company UpdateAug 14, 2025424B5424B5Jun 25, 20258-KMaterial Agreement · Company UpdateJun 25, 2025424B5424B5Jun 24, 20258-KReg FD Disclosure · Company UpdateJun 23, 20258-KShareholder VoteMay 30, 202510-Q10-QMay 15, 20258-KResults of OperationsMay 15, 2025DEF 14ADEF 14AApr 30, 20258-KCompany UpdateApr 18, 20258-KResults of OperationsApr 4, 202510-K10-KMar 28, 20258-KExecutive Change · Shareholder VoteJan 24, 2025DEF 14ADEF 14ADec 31, 20248-KCompany UpdateDec 3, 20248-KMaterial Agreement · Equity IssuanceNov 20, 202410-Q10-QNov 14, 20248-KResults of OperationsNov 14, 20248-KExecutive Change · Company UpdateSep 20, 20248-KSecurity-Holder Rights · Bylaw AmendmentAug 30, 20248-KExecutive Change · Shareholder VoteAug 22, 20248-KResults of Operations · Company UpdateAug 14, 202410-Q10-QAug 14, 2024DEF 14ADEF 14AJul 30, 20248-KMaterial Agreement · Company UpdateJun 14, 202410-Q10-QMay 13, 20248-KResults of Operations · Company UpdateMay 13, 202410-K/A10-K/AApr 29, 202410-K10-KMar 18, 20248-KResults of Operations · Company UpdateMar 18, 20248-K/AShareholder VoteFeb 16, 2024SC 13GSC 13GFeb 14, 20248-KAuditor ChangeDec 8, 202310-Q10-QNov 13, 20238-K/AShareholder VoteSep 26, 20238-KExecutive Change · Shareholder VoteSep 20, 20238-KDelisting NoticeSep 20, 2023SC 13GFORTE BIOSCIENCES, INC.Sep 12, 2023SC 13GSC 13GSep 8, 2023DEFA14ADEFA14ASep 1, 2023DEFA14ADEFA14AAug 31, 2023SC 13DTHE SCHEDULE 13DAug 23, 202310-Q10-QAug 14, 2023SC 13GSCHEDULE 13GAug 10, 2023SC 13GSC 13GAug 10, 20238-KAuditor ChangeAug 4, 20238-KMaterial Agreement · Equity IssuanceAug 1, 20238-KMaterial Agreement · Security-Holder RightsJun 26, 202310-Q10-QMay 15, 202310-K/A10-K/AMay 1, 2023SC 13GSC 13GApr 10, 20238-KResults of OperationsMar 31, 202310-K10-KMar 31, 20238-KBylaw AmendmentFeb 9, 20238-KExecutive Change · Reg FD DisclosureJan 12, 202310-Q10-QNov 14, 20228-KExecutive Change · Results of OperationsNov 14, 20228-KResults of Operations · Company UpdateAug 15, 202210-Q10-QAug 15, 20228-KCompany UpdateAug 12, 2022424B5424B5Aug 12, 2022SC 13DSC 13DAug 4, 2022SC 13DSC 13DAug 1, 20228-KMaterial Agreement · Security-Holder RightsJul 12, 2022SC 13GSC 13GJul 8, 2022SC 13DTHE SCHEDULE 13DJul 5, 20228-KExecutive Change · Reg FD DisclosureJun 7, 20228-KShareholder VoteJun 2, 2022
Insider Activity
In the 90 days to Dec 30, 2025: 1 insider bought $255K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 30, 2025 | Riley Antony ACHIEF FINANCIAL OFFICER | Buy | 9,680 | $26.33 | $255K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance